Cell Viability Assays Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Description

The Global Cell Viability Assays Market was valued at USD 1.7 billion in 2023 and is projected to grow at a CAGR of 8.5% over the forecast period. This growth is driven by the increased adoption of precision medicine and advancements in biotechnology, fueling the demand for reliable and accurate cell viability testing. In addition, the rising prevalence of chronic diseases, such as cancer and cardiovascular disorders, underscores the need for efficient drug discovery processes and novel therapeutics, which heavily rely on cell viability assays.

The market benefits from a surge in clinical trials and early-stage drug testing, alongside expanding research activities in cellular and molecular biology. Increased funding for research and development, coupled with the adoption of advanced technologies like automated assays and high-throughput screening, further propels the market expansion.

Cell viability assays are essential in various biomedical research fields, including toxicology, drug development, and cell biology, as they assess a cell's ability to survive and function under specific circumstances. These assays are critical for determining the effects of chemicals, treatments, or environmental changes on cell health.

The market is segmented based on Product, Application, End-user, and Region.

In 2023, the consumables segment dominated with a 62.4% market share, driven by the frequent use of reagents, assay kits, and microplates, which are essential for routine research. In terms of applications, stem cell research was valued at USD 713.3 million, driven by the rising demand for stem cell-based treatments. The growing focus on regenerative medicine and the broad applications of stem cells in disease modeling and personalized medicine also contribute to the segment growth.

Among end-users, biopharmaceutical and pharmaceutical companies are expected to grow at 8.6% CAGR, as they heavily rely on cell viability assays in drug development. Regulatory requirements and substantial investments in research and development further support this segment's dominance.

North America accounted for USD 696 million in the cell viability assays market in 2023, with a projected growth rate of 8.3% CAGR. The U.S. alone accounted for USD 641 million in 2023 and is expected to reach USD 1.3 billion by 2032, driven by advanced technology, a supportive regulatory framework, and significant investments in research. The U.S. market benefits from its adoption of cutting-edge technologies, enhancing the accuracy and efficiency of cell viability testing.

Product Code: 10906

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increased drug discovery and development
  - 3.2.1.2 Advancements in cell-based assays
  - 3.2.1.3 Increasing stem cell research
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of advanced assays and instruments
  - 3.2.2.2 Technical complexity requiring expertise
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Consumables
- 5.2.1 Assay kits
  - 5.2.1.1 Tetrazolium reduction assay kits
    - 5.2.1.1.1 MTT assays
    - 5.2.1.1.2 MTS assays
    - 5.2.1.1.3 XTT assays
    - 5.2.1.1.4 Other tetrazolium reduction assay kits
  - 5.2.1.2 Resazurin cell viability assay kits
  - 5.2.1.3 Calcein-AM cell viability assay kits
  - 5.2.1.4 Other assay kits
- 5.2.2 Reagents
- 5.2.3 Microplates
5.3 Instruments
- 5.3.1 Spectrophotometers
- 5.3.2 Flow cytometers
- 5.3.3 Automated cell counters
- 5.3.4 Microscopy
- 5.3.5 Cell imaging and analysis systems

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Stem cell research
6.3 Drug discovery and development
6.4 Basic research
6.5 Clinical and diagnostic applications
6.6 Other applications

Chapter 7 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Biopharmaceutical and pharmaceutical companies
7.3 CROs and CMOs
7.4 Academic and research institutes
7.5 Diagnostic laboratories

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

9.1 Abcam plc
9.2 Abnova Corporation
9.3 Becton, Dickinson and Company
9.4 Bio-Rad Laboratories, Inc.
9.5 BioTek Instruments, Inc. (Agilent Technologies, Inc.)
9.6 Biotium, Inc.
9.7 Canvax Biotech S.L.
9.8 Creative Bioarray, Inc.
9.9 Danaher Corporation
9.10 Geno Technology, Inc.
9.11 GE Healthcare Technologies, Inc.
9.12 Merck KGaA
9.13 PerkinElmer, Inc.
9.14 Promega Corporation
9.15 Thermo Fisher Scientific Inc.